Skip to main content
SpringerLink
Log in

Prostatakarzinom

  • Chapter
Therapiekonzepte Onkologie

  • 33 Accesses

Zusammenfassung

95% aller Prostatakarzinome sind Adenokarzinome. Sie entstehen aus dem Epithel der peripheren azinären Prostatadrüsen. Die verbleibenden Karzinome stellen überwiegend Tumoren des Übergangsepithels des intraprostatischen Anteils der Urethra und der Einmündungen der Samenkanäle in den proximalen Anteil der Urethra dar. In diesem Kapitel werden ausschließlich die Adenokarzinome der Prostata dargestellt.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Carter BS, Carter HB, Isaacs JT (1990) Epidemiologic evidence regarding predisposing factors to prostate cancer. The Prostate 16: 187–197

    Article  PubMed  CAS  Google Scholar 

  2. Devesa SS, Silverman DT, Young JL, Pollack ES et al. (1987) Cancer incidence and mortality trends among whites in the United States, 1947–1984. J Natl Cancer Inst 79: 701–770

    PubMed  CAS  Google Scholar 

  3. Zaddze DG, Boyle P (1987) Cancer of the prostate: epidemiology and aetiology. Br J Urol 59: 493–502

    Article  Google Scholar 

  4. Meikle AW, Smith JA Jr (1990) Epidemiology of prostate cancer. Urol Clin North Amer 17: 709–718

    CAS  Google Scholar 

  5. Walsh EA (1992) In: Campbell’s Urology, 6th ed. Saunders Company, 1162

    Google Scholar 

  6. Gleason DF, Veterans Administration Cooperative Urological Research Group (1977) In: Tannebaum M (ed) Urologic Pathology: The Prostate. Lea and Febiger, Philadelphia, 9: 171197

    Google Scholar 

  7. Gardner WA Jr, Coffey D, Karr JP, Chiarodo A et al. (1988) A uniform histopathologic grading system for prostate cancer. Human Pathology 19: 119–120

    Article  PubMed  Google Scholar 

  8. Murphy GP, Whitmore W Jr (1979) A report of the workshops on the current status of the histologic grading of prostate cancer. Cancer 44: 1490–1494

    Article  PubMed  CAS  Google Scholar 

  9. TNM Classification (1992) Fourth Edition 2nd revision 1992. In: UICC, Hermanek P, Sobin LH (eds). Springer, Berlin Heidelberg, 141–144

    Google Scholar 

  10. Schröder FH, Hermanek P, Denis L, Fair WR, Gospodarowicz MK, Pavone-Macaluso M (1992) The TNM classification of Prostate Cancer. The Prostate (Suppl 4 ): 129–138

    Article  Google Scholar 

  11. Schröder FH, Ouden D van den, Davidson P (1992) The Limits of Surgery in the Cure of Prostatic Carcinoma. EBU 1, 3: 18–23

    Google Scholar 

  12. Kozlowski JM, Ellis WJ, Grayhack JT (1991) Advanced prostatic carcinoma. Early versus late endocrine therapy. Urol Clin North Amer 18: 15–24

    Google Scholar 

  13. Oesterling JE (1992) Prostate-specific antigen and prostate cancer. Current Opinion in Urology 2: 348–355

    Article  Google Scholar 

  14. Oesterling JE (1991) Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 145: 907–923

    PubMed  CAS  Google Scholar 

  15. Cooner WH, Mosley BR, Rutherford CL Jr, Beard JH, Pond HS et al. (1990) Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen. J Urol 143: 1146–1154

    PubMed  CAS  Google Scholar 

  16. Perrin P (1992) Transrectal ultrasound for the diagnosis and staging of prostate cancer. Current Opinion in Urology 3: 344–347

    Article  Google Scholar 

  17. Ebert T, Schmitz-Dräger BJ, Bürrig KF, Miller S, Pauli N, Kahn T, Ackermann R (1992) Accuracy of imaging modalities in staging the local extent of prostate cancer. Urol Clin North Amer 18: 453–457

    Google Scholar 

  18. Whitesel JA, Donohue RE, Mani JH, Mohr S, Scanvino DJ, Augspurger RR, Biber RJ, Fauver HE, Wettlaufer JN, Pfister RR (1984) Acid phosphatase: its influence on the management of carcinoma of the prostate. J Urol 131: 70–72

    PubMed  CAS  Google Scholar 

  19. Stamey TA, Kabalin IN, McNeal JE, Johnstone IM, Freiha F, Redwine EA, Yang N (1989) Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. Il. Radical prostatectomy treated patients. J Urol 141: 1076–1083

    Google Scholar 

  20. Whitmore WF, Warner JA, Thompson IM (1991) Expectant management of localized prostatic cancer. Cancer 67: 1091–1096

    Article  PubMed  Google Scholar 

  21. Carr TU/, Neal DE, Powell PH, Hall RR (1988) Conservative management of prostate cancer. The Lancet: 776–777

    Google Scholar 

  22. George NJR (1988) Natural history of localized prostatic cancer managed by conservative therapy alone. The Lancet: 494–497

    Google Scholar 

  23. Johansson JE, Andersson SO, Krusemo UB, Adami HO, Bergstrom R, Kraa7 W (1989) Natural history of localized prostatic cancer. The Lancet:799–803

    Google Scholar 

  24. Jones GW (1992) Prospective conservative management of localized prostate cancer. Cancer 70: 307–310

    Article  PubMed  CAS  Google Scholar 

  25. Schellhammer P, Debruyne F, Altwein J, Ambrose S, Jones G, Schmidt J, Smith J, Zincke H (1992) Locoregional disease. Cancer (Suppl 1 ) 70: 362–364

    Article  Google Scholar 

  26. Stamey TA, Kabalin JN (1989) Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate I. Untreated patients. J Urol 141: 1070–1075

    Google Scholar 

  27. Walsh PC, Donker PJ (1982) Impotence following radical prostatectomy: insight into etiology and prevention. J Urol 128: 492–497

    PubMed  CAS  Google Scholar 

  28. Walsh PC, Lepor H, Eggleston JC (1983) Radical prostatectomy with preservation of sexual function: anatomical and pathological considerations. The Prostate 4: 473–485

    Article  PubMed  CAS  Google Scholar 

  29. Freiha FS, Bagshaw MA (1984) Carcinoma of the prostate: results of post-irradiation biopsy. The Prostate 5: 19–25

    Article  PubMed  CAS  Google Scholar 

  30. Kabalin JN, Hodge KK, McNeal JE, Freiha FS, Stamey TA (1989) Identification of residual cancer in the prostate following radiation therapy: role of transrectal ultrasound guided biopsy and prostate specific antigen. J Urol 142: 326–331

    PubMed  CAS  Google Scholar 

  31. Eggleston JC, Walsh PC (1985) Radical prostatectomy with preservation of sexual function: pathological findings in the first 100 cases. J Urol 134: 1146–1148

    PubMed  CAS  Google Scholar 

  32. Catalona WJ, Bigg SW (1990) Nerve-sparing radical prostatectomy: evaluation of results after 250 patients. J Urol 143: 538–544

    PubMed  CAS  Google Scholar 

  33. Stamey TA, Villers AA, McNeal JE, Link PC, Freiha FS (1990) Positive surgical margins at radical prostatectomy: importance of the apical dissection. J Urol 143: 1166–1173

    PubMed  CAS  Google Scholar 

  34. McNeal JE, Villers Al, Redwine EA, Freiha FS, Stamey TA (1990) Histologic differentiation, cancer volume, and pelvic lymph node metastasis in adenocarcinoma of the prostate. Cancer 66: 1225–1233

    Article  PubMed  CAS  Google Scholar 

  35. Cantrell BB, DeKlerk DP, Eggleston JC, Boitnott JK, Walsh PC (1981) Pathological factors that influence prognosis in stage A prostate cancer: the influence of extent versus grade. J Urol 125: 516–520

    PubMed  CAS  Google Scholar 

  36. Steinberg GD, Epstein JI, Piantadosie S, Walsh PC (1990) Management of stage D1 adenocarcinoma of the prostate: the Johns Hopkins experience 1974 to 1987. J Urol 144: 1425–1432

    PubMed  CAS  Google Scholar 

  37. Walsh EA (1992) In: Campbell’s Urology, 6th ed. Saunders Company, 1201–1202

    Google Scholar 

  38. Gibbons RP, Mason TJ, Correra RJ Jr, Cummings KB, Taylor WJ, Hafermann MD, Richardson RG (1979) Carcinoma of the prostate: local control with external beam radiation therapy. J Urol 121: 310–312

    PubMed  CAS  Google Scholar 

  39. Holzmann M, Seale-Hawkins C, Scardino PT (1989) The frequency and morbidity of local tumor recurrences after definitive radiotherapy for stage C prostate cancer. J Urol 141: 347

    Google Scholar 

  40. Kuban DA, Schellhammer PF, El-Mandi AM (1991) Hemibody irradiation in advanced prostatic carcinoma. Urol Clin North Amer 18: 131–137

    CAS  Google Scholar 

  41. Flynn DF, Shipley WU (1991) Management of spinal cord compression secondary to metastatic prostatic carcinoma. Urol Clin North Amer 18: 145–152

    CAS  Google Scholar 

  42. Montie JE (1990) Significance and treatment of positive margins or seminal vesicle invasion after radical prostatectomy. Urol Clin North Amer 17: 803–812

    CAS  Google Scholar 

  43. Sogani PC, Fair WR (1987) Treatment of advanced prostatic cancer. Urol Clin North Amer 14: 353–371

    CAS  Google Scholar 

  44. Kramolowsky EF (1988) The value of testosterone deprivation in stage D1 carcinoma of the prostate. J Urol 139: 1242–1244

    PubMed  CAS  Google Scholar 

  45. Aubel van OGJM, Hoekstra WJ, Schroer FH (1985) Early orchiectomy for patients with stage D1 prostatic carcinoma. J Urol 134: 292–294

    Google Scholar 

  46. Zincke H (1989) Extended experience with surgical treatment of stage D1 adenocarcinoma of prostate. Urology, XXXXIII (Suppl): 27–36

    Article  Google Scholar 

  47. Zincke H, Utz DG, Taylor WF (1986) Bilateral pelvic lymphadenectomy and radical prostatectomy for clinical stage C prostatic cancer: role of adjuvant treatment for residual cancer and in disease progression. J Urol 135: 1199–1205

    PubMed  CAS  Google Scholar 

  48. DeKemion JB, Neuwirth H, Stein A, Dorey F, Stenzl A, Hannah J, Blyth B (1990) Prognosis of patients with stage D1 prostate carcinoma following radical prostatectomy with and without early endocrine therapy. J Urol 144: 700–703

    Google Scholar 

  49. Myers RP, Zincke H, Fleming TR, Farrow GM, Furlow WL, Utz DC (1983) Hormonal treatment at time of radical retropubic prostatectomy for stage D1 prostate cancer. J Urol 130: 99–101

    PubMed  CAS  Google Scholar 

  50. Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA, Blumenstein BA, Davis MA, Goodman PJ (1989) A controlled trial of Leuprolide with and without flutamide in prostatic carcinoma. New Engl J Med 312: 419–424

    Article  Google Scholar 

  51. Keuppens F, Denis L, Smith P, Pinto Carvalho A, Newling D, Bond A, Sylvester R, Pauw de M, Vermeylen K, Ongena P, EORTC GU Group (1990) Zoladex and flutamide versus bilateral orchiectomy. Cancer 66: 1045–1057

    Google Scholar 

  52. Labrie F, Dupont A, Giguere M, Borsanyl JP, Lacourciere Y, Monfette G, Emond J, Bergeron N (1988) Benefits of combination therapy with flutamide in patients relapsing after castration. Br J Urol 61: 341–346

    Article  PubMed  CAS  Google Scholar 

  53. Trachtenberg J,Halpern N, Pont A (1983) Ketoconazole: a novel and rapid treatment for advanced prostatic cancer. J Urol 130: 152–153

    Google Scholar 

  54. Isaacs JT, Coffey DS (1981) Adaptation versus selection as the mechanism responsible for the relapse of prostatic cancer to androgen ablation therapy as studied in the Dunning R-3327-H adenocarcinoma. Cancer Res 1: 5050–5075

    Google Scholar 

  55. Isaacs JT, Wake N, Coffey DS, Sandberg M (1982) Genetic instability coupled to clonal selection as a mechanism for tumor progression in the Dunning R-3327 rat prostatic adenocarcinoma system. Cancer Res 42: 2353–2361

    PubMed  CAS  Google Scholar 

  56. Eisenberger MA (1988) Chemotherapy for prostate cancer. NCI Monogr 7: 151–163

    PubMed  Google Scholar 

  57. Eisenberger MA (1990) Chemotherapy for endocrine resistant cancer of the prostate. EORTC Genitourinary Group Monograph 8: 155–164

    Google Scholar 

  58. Robinson RG, Mebust WK, Davis BE, Weigel JW, Baxter KG (1990) Treatment of metastatic prostate carcinoma in bone with strontium 89. J Urol: 222

    Google Scholar 

  59. Janknegt RA, Abbou CC, Bartoletti R, Bernstein-Hahn L, Bracken B, Brisset JM, Calaos da Silva F, Chisholm G, Crawford ED, Debruyne FMJ, Dijkman GD, Frick J, Goedhals L, Knönagel, Venner PM (1993) Orchiectomy and Nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial. J Urol 149: 77–83

    PubMed  CAS  Google Scholar 

  60. Smith JA Jr, Haynes TH, Middleton RG (1984) Impact of external irradiation on local symptoms and survival free of disease in patients with pelvic lymph node metastasis from adenocarcinoma of the prostate. J Urol 131: 705–707

    PubMed  Google Scholar 

  61. Crawford ED, Blumenstein BA, Goodman PJ, Davis MA, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA (1990) Leuprolide with and without flutamide in advanced prostate cancer. Cancer 66: 1039–1044

    PubMed  CAS  Google Scholar 

  62. Béland G, Elhilali M, Fradet Y, Laroche B, Ramsey EW, Trachtenberg J, Venner PM, Tewari HD (1990) A controlled trial of castration with and without nilutamide in metastatic prostatic carcinoma. Cancer 66: 1074–1079

    PubMed  Google Scholar 

  63. Iversen P, Christensen MG, Friis E, Hombøl, Hvidt V, Iversen HG, Klarskov P, Krarup T, Lund F, Mogensen P, Pedersen T, Rasmussen F, Rose C, Skaarup P, Wolf H (1990) A phase Ill trial of Zoladex and Flutamide versus orchiectomy in the treatment of patients with advanced carcinoma of the prostate. Cancer 66: 1058–1066

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. P. W. P. Delcourt
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. F. M. J. Debruyne
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Innere Klinik und Poliklinik (Tumorforschung), Westdeutsches Tumorzentrum Essen, Universitätsklinikum Essen, Hufelandstraße 55, 45122, Essen, Deutschland

    Siegfried Seeber  & Jochen Schütte  & 

Rights and permissions

Reprints and permissions

Copyright information

© 1993 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Delcourt, P.W.P., Debruyne, F.M.J. (1993). Prostatakarzinom. In: Seeber, S., Schütte, J. (eds) Therapiekonzepte Onkologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-10495-8_38

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-10495-8_38

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-56872-8

  • Online ISBN: 978-3-662-10495-8

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation